Mackenzie Financial
NTLA icon

Mackenzie Financial’s Intellia Therapeutics NTLA Stock Holding History

Mackenzie Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,922
Closed -$275K – 1543
2022
Q3 		$275K Sell
4,922
-264
-5% -$16.4K ﹤0.01% 1125
2022
Q2 		$268K Buy
5,186
+1,391
+37% +$70.6K ﹤0.01% 1138
2022
Q1 		$276K Buy
3,795
+137
+4% +$11.6K ﹤0.01% 1155
2021
Q4 		$433K Sell
3,658
-1,998
-35% -$250K ﹤0.01% 1024
2021
Q3 		$759K Buy
5,656
+3,521
+165% +$533K ﹤0.01% 945
2021
Q2 		$346K Buy
+2,135
New +$166K ﹤0.01% 1042

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Mackenzie Financial's NTLA Position: Q4 2022 in Review

Mackenzie Financial sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 4,922 shares — an estimated $275K sold.

Mackenzie Financial first reported a position in NTLA in Q2 2021 and held it in 6 quarters. The position peaked at $759K in Q3 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Mackenzie Financial reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Mackenzie Financial sold 4,922 Intellia Therapeutics shares in Q4 2022, an estimated $275K.
  • Mackenzie Financial first reported a position in Intellia Therapeutics in Q2 2021 and held it in 6 quarters.
  • Mackenzie Financial's Intellia Therapeutics position peaked at $759K in Q3 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Mackenzie Financial's 13F filing for Q4 2022, filed 14 Feb 2023.